Sign In
Buy ELVN
$59.42
-1.04 (-1.72%)
At Close: Aug 10, 2026
Dimensional Fund Advisors LP Raises Holdings in Enliven Therapeutics, Inc. $ELVN
04:03am, Thursday, 06'th Aug 2026
Dimensional Fund Advisors LP lifted its position in shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) by 70.9% in the undefined quarter, according to its most recent 13F filing with the SEC. The fir
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
04:05pm, Wednesday, 05'th Aug 2026
Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile Reached alignment with the FDA on key P
Enliven Therapeutics, Inc. $ELVN is Avidity Partners Management LP’s 6th Largest Position
03:50am, Saturday, 01'st Aug 2026
Avidity Partners Management LP increased its stake in Enliven Therapeutics, Inc. (NASDAQ: ELVN) by 185.1% during the first quarter, according to the company in its most recent 13F filing with the SEC.
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
03:36pm, Saturday, 27'th Jun 2026
This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gains and early clinical progress.
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
12:03pm, Saturday, 27'th Jun 2026
Orbimed Advisors reported selling 860,123 shares of ELVN on June 22, 2026, generating a transaction value of approximately $39.0 million at an average price of $45.36 per share. This transaction repre
BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and developme
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
11:00pm, Thursday, 11'th Jun 2026
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants PR Newswire
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
10:39pm, Thursday, 11'th Jun 2026
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and developme
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:05pm, Thursday, 11'th Jun 2026
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and developmen
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
08:00am, Thursday, 11'th Jun 2026
61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort 67% overall MMR and 55% MMR achievement by 24 weeks in all Phase 1b patients who had previously received 1 or 2 prio
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
04:05pm, Wednesday, 03'rd Jun 2026
Enliven will host a webcast conference call on June 11, at 8:30 a.m. ET BURLINGAME, Calif.
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.
05:25pm, Monday, 01'st Jun 2026
This oncology-focused biotech, advancing kinase inhibitors for cancer, reported a notable insider sale amid strong one-year stock gains.
Enliven Therapeutics to Present at Upcoming Investor Conferences
04:05pm, Thursday, 21'st May 2026
BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
04:46pm, Wednesday, 13'th May 2026
This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials.
